With effect from July 1, 2025, the new term runs until June 30, 2028. “Under the leadership of Dr Traeger, Jenoptik has been very successful in recent years in developing into a profitably growing, focused photonics group. Continuity in the management of the company by Dr Traeger creates the basis for realizing the organic growth potential and thus consistently implementing our strategy,” said Matthias Wierlacher, chairman of the Jenoptik supervisory board.
“I look forward to continuing to work with my colleagues on the executive board, employees, customers and shareholders and thank the supervisory board for the trust they have placed in me,” said Traeger. “I would like to continue the successful path we have embarked on together.”
Together with the other members of the executive board, Dr Traeger has been shaping the strategic realignment and focus of the company since 2017. The core of the “More Value” agenda is to focus Jenoptik’s leading technological expertise on the fast-growing future markets of semiconductor and electronics, life science and medical technology, and smart mobility. As an “enabler”, the company can create significant added value (“More Value”) for customers, employees and shareholders with its photonic solutions and accordingly achieve above-average growth and an increase in profitability.
